drugset
drugset / Trial / NCT02415036

Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma

NCT02415036 ↗

Phase 2 Terminated 17 enrolled Delcath Systems Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a two arm, open label, multi-center, Phase 2 study to evaluate the efficacy and safety of Melphalan/HDS in patients with unresectable Hepatocellular Carcinoma (HCC) or Intra Hepatic Cholangiocarcinoma (ICC) confined to the liver.

Timeline

Start
2014-06
Primary completion
2018-10
Completion
2018-12

Outcome

Outcome not reported

Stopped (Enrollment): “Limited enrollment”

Drugs

EvaluationDrugModalityDoseRoute
Subject Melphalan Small molecule 3 mg/kg Other

Indications

hepatocellular carcinoma intrahepatic cholangiocarcinoma